Kreaxi
  • Home
  • Company
  • Funds
  • Team
  • Portfolio
  • News
  • Contact
  • Français
Select Page

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

Alizé Pharma 3, a company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announces that it has completed a €67 million Series A financing round. The oversubscribed Series A was led by LSP, and included Novo Ventures,...

MailClark raises $900k in Second Round from Kreaxi and IT-Translation Investment

After a first round of $350k in January 2016, the French startup MailClark just announced that it has raised $900k in a second round led by Kreaxi, with participation from existing investor IT Translation as well as private and public funds. Founded in December 2014,...

Symetis and Boston Scientific reach USD 435 million purchase agreement

– Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment – Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease –...

Recent Posts

  • Theranexus presents an update on the progress of its main programs and announces its cash position as of 31 December 2020. Implemantation of a new equity line.
  • Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
  • Theranexus, Lyon Neuroscience Research Center and CERMEP announce the creation and funding of new joint public/ private laboratory “NeuroImaging for Drug Discovery” (NI2D)
  • Amolyt Pharma announces research collaboration with PeptiDream
  • The Food and Drug Administration (FDA) issues a favorable opinion on the preclinical development plan submitted by Theranexus and BBDF

Recent Comments

    Archives

    • January 2021
    • December 2020
    • November 2020
    • October 2020
    • September 2020
    • July 2020
    • April 2020
    • January 2020
    • December 2019
    • November 2019
    • October 2019
    • September 2019
    • July 2019
    • March 2019
    • February 2019
    • December 2018
    • November 2018
    • December 2017
    • September 2017
    • April 2017

    Categories

    • News portfolio

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    About us

    Kreaxi is an investment management firm specialized in the equity financing of innovative, deeptech & lowtech startups with high growth potential. Kreaxi manages regional funds in France, active in Auvergne-Rhône-Alpes region (89m€) as well as national funds (71m€).

    Lyon

    101, Chemin Vert
    69760 Limonest 
    France

    +33 4 72 52 39 39

    Paris

    13-15 rue Taitbout
    75009 Paris
    France

    +33 1 73 02 89 69

    Register to recieve our Krea-Venture newsletter

    • Twitter
    © 2021 Kreaxi. Tous droits réservés. Mentions légales. Informations réglementaires. Démarche ESG.